1Clavel G, Bessis N, Boissier MC. Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine, 2003, 70:321-326.
2Weber A J, Bandt MD. Angiogenesis: general mechanisms and implications for rheumatoid arthritis. Joint Bone Spine, 2000, 67:573-592.
3Latour F, Zabraniecki L, Dromer C, et al. Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction: A clinical, radiological, and pathological study in 12 patients monitored for 10 years, joint Bone Spine, 2001, 68: 493-498.
4Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta, 2004, 1654: 13-22.
5Nagashima M, Asano G, Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol, 2000, 27: 2339-2342.
6Reijerkerk A, Voest EE, Gebbink MFBG. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer, 2000, 36: 1695-1705.
7Dixelius J, Cross M J, Matsumoto T, et al. Endostatin action and intracellular signaling: 13-catenin as a potential target. Cancer Lett, 2003, 196: 1-12.
8Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis.Curr Opin Pharmacol, 2003, 3: 317-322.
9Yin G, Liu W, An P, et al. Endostatin Gene transfer inhibits joint angiogenesis and pannus formation in inflammatory Arthritis. Mol Ther, 2002, 5: 547-554.
10Eriksson K, Magnusson P, Dixelius J, et al. Angiostatin and endostatin inhibit endo;thelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett, 2003, 536: 19-24.
